First Tracks Biotherapeutics (NASDAQ:TRAX) Price Target Raised to $70.00

First Tracks Biotherapeutics (NASDAQ:TRAX) had its price target lifted by Wedbush from $60.00 to $70.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

TRAX has been the subject of several other reports. Zacks Research raised First Tracks Biotherapeutics to a “hold” rating in a research note on Monday, April 27th. JPMorgan Chase & Co. began coverage on First Tracks Biotherapeutics in a research report on Thursday, April 23rd. They set an “overweight” rating and a $31.00 target price on the stock. HC Wainwright upped their target price on First Tracks Biotherapeutics from $44.00 to $57.00 and gave the company a “buy” rating in a report on Thursday. Leerink Partners started coverage on First Tracks Biotherapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $46.00 price target for the company. Finally, Barclays lifted their price target on First Tracks Biotherapeutics from $48.00 to $65.00 and gave the stock an “overweight” rating in a research note on Thursday. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $60.50.

First Tracks Biotherapeutics Stock Performance

Shares of First Tracks Biotherapeutics stock opened at $44.04 on Thursday. First Tracks Biotherapeutics has a 12-month low of $14.72 and a 12-month high of $49.91. The stock has a market capitalization of $1.54 billion and a PE ratio of -23.93. The firm has a 50-day moving average of $30.39.

First Tracks Biotherapeutics (NASDAQ:TRAX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.21). On average, research analysts predict that First Tracks Biotherapeutics will post -4.02 earnings per share for the current fiscal year.

Key First Tracks Biotherapeutics News

Here are the key news stories impacting First Tracks Biotherapeutics this week:

• Positive Sentiment: Wedbush forecast significant potential price appreciation for TRAX, reinforcing the bullish view that the company’s long-term opportunity may outweigh its current losses. Wedbush Forecasts Strong Price Appreciation for First Tracks Biotherapeutics
• Positive Sentiment: Barclays maintained its Buy rating on First Tracks Biotherapeutics, signaling continued confidence in the company despite near-term earnings weakness. Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics
• Positive Sentiment: HC Wainwright raised its EPS forecasts for fiscal 2027 and 2028, reducing projected losses to $3.83 and $3.84 per share, respectively. The firm retained a Buy rating and a $57 price target, implying upside from recent trading levels.
• Neutral Sentiment: Analyst coverage remains mixed: HC Wainwright’s long-term forecasts still anticipate sizable losses, but the firm expects losses to narrow substantially by 2030. The outlook suggests investors remain focused on execution and the path toward profitability.
• Negative Sentiment: HC Wainwright lowered its estimates for third-quarter and fourth-quarter 2026 EPS to losses of $0.96 and $1.00, respectively, and cut its full-year 2026 estimate to a $4.35 loss from $3.55. It also reduced its 2029 and 2030 forecasts, indicating greater expected near- and long-term cash burn.
• Negative Sentiment: The stock declined following weak earnings. First Tracks Biotherapeutics reported a quarterly loss of $0.95 per share, worse than the $0.74 consensus estimate, adding pressure to a company that analysts expect to remain unprofitable this year. First Tracks Biotherapeutics Shares Down Following Weak Earnings

About First Tracks Biotherapeutics

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.